ASSEMBLY BIOSCIENCES INC (ASMB)

Company Profile

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 68 full-time employees. The company went IPO on 2010-12-17. Its hepatitis B virus (HBV) pipeline includes potent, HBV core inhibitors in clinical development, which are designed to disrupt the virus replication cycle at several key points with a focus on achieving finite treatment and functional cures. Its HBV and hepatitis delta virus (HDV) pipeline also includes two complementary approaches: a viral entry inhibitor and an oral, liver-focused, interferon-alpha receptor agonist, with potential application for both HBV and as chronic suppressive therapy for HDV, which is associated with increased disease burden for HBV/HDV patients. The herpesvirus pipeline addresses two serious consequences associated with herpesvirus infections, high-recurrence genital herpes and transplant-associated herpesviruses. Its HBV and HDV programs include ABI-4334 (4334), ABI-5366 (5366), HBV/HDV inhibitor program, and others.

Company Info

ASSEMBLY BIOSCIENCES INC

Two Tower Place, 7Th Floor

South San Francisco CALIFORNIA 94080

P: 18334094583

CEO: John G. McHutchison

Employees: 68

Website: https://www.assemblybio.com/